INTRODUCTION: Esophageal adenocarcinomas (EAC) are aggressive cancers that are increasing in incidence and associated with a poor prognosis. The identification of highly expressed genes in EAC relative to metaplastic Barrett's esophagus (BE) may provide new targets for novel early cancer detection strategies using endoscopically administered, fluorescently labeled peptides. METHODS: Gene expression analysis of BE and EACs were used to identify the cell surface marker transglutaminase 2 (TGM2) as overexpressed in cancer. The expression of two major isoforms of TGM2 was determined by qRT-polymerase chain reaction in an independent cohort of 128 EACs. Protein expression was confirmed by tissue microarrays and immunoblot analysis of EAC cell lines. TGM2 DNA copy number was assessed using single nucleotide polymorphism microarrays and confirmed by qPCR. TGM2 expression in neoadjuvantly treated EACs and following small interfering RNA-mediated knockdown in cisplatin-treated EAC cells was used to determine its possible role in chemoresistance. RESULTS: TGM2 is overexpressed in 15 EACs relative to 26 BE samples. Overexpression of both TGM2 isoforms was confirmed in 128 EACs and associated with higher tumor stage, poor differentiation, and increased inflammatory and desmoplastic response. Tissue microarrays and immunohistochemistry confirmed elevated TGM2 protein expression in EAC. Single nucleotide polymorphism and qPCR analysis revealed increased TGM2 gene copy number as one mechanism underlying elevated TGM2 expression. TGM2 was highly expressed in resistant EAC after patient treatment with neoadjuvant chemotherapy/radiation suggesting a role for TGM2 in chemoresistance. CONCLUSION: TGM2 may be a useful cell surface biomarker for early detection of EAC.
INTRODUCTION:Esophageal adenocarcinomas (EAC) are aggressive cancers that are increasing in incidence and associated with a poor prognosis. The identification of highly expressed genes in EAC relative to metaplastic Barrett's esophagus (BE) may provide new targets for novel early cancer detection strategies using endoscopically administered, fluorescently labeled peptides. METHODS: Gene expression analysis of BE and EACs were used to identify the cell surface marker transglutaminase 2 (TGM2) as overexpressed in cancer. The expression of two major isoforms of TGM2 was determined by qRT-polymerase chain reaction in an independent cohort of 128 EACs. Protein expression was confirmed by tissue microarrays and immunoblot analysis of EAC cell lines. TGM2 DNA copy number was assessed using single nucleotide polymorphism microarrays and confirmed by qPCR. TGM2 expression in neoadjuvantly treated EACs and following small interfering RNA-mediated knockdown in cisplatin-treated EAC cells was used to determine its possible role in chemoresistance. RESULTS:TGM2 is overexpressed in 15 EACs relative to 26 BE samples. Overexpression of both TGM2 isoforms was confirmed in 128 EACs and associated with higher tumor stage, poor differentiation, and increased inflammatory and desmoplastic response. Tissue microarrays and immunohistochemistry confirmed elevated TGM2 protein expression in EAC. Single nucleotide polymorphism and qPCR analysis revealed increased TGM2 gene copy number as one mechanism underlying elevated TGM2 expression. TGM2 was highly expressed in resistant EAC after patient treatment with neoadjuvant chemotherapy/radiation suggesting a role for TGM2 in chemoresistance. CONCLUSION:TGM2 may be a useful cell surface biomarker for early detection of EAC.
Authors: Elizabeth L Bird-Lieberman; André A Neves; Pierre Lao-Sirieix; Maria O'Donovan; Marco Novelli; Laurence B Lovat; William S Eng; Lara K Mahal; Kevin M Brindle; Rebecca C Fitzgerald Journal: Nat Med Date: 2012-01-15 Impact factor: 53.440
Authors: Amy L Silvers; Lin Lin; Adam J Bass; Guoan Chen; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Thomas J Giordano; Mark B Orringer; David G Beer; Andrew C Chang Journal: Clin Cancer Res Date: 2010-03-23 Impact factor: 12.531
Authors: L Nagy; M Saydak; N Shipley; S Lu; J P Basilion; Z H Yan; P Syka; R A Chandraratna; J P Stein; R A Heyman; P J Davies Journal: J Biol Chem Date: 1996-02-23 Impact factor: 5.157
Authors: Christian F Singer; Gernot Hudelist; Ingrid Walter; Ernst Rueckliniger; Klaus Czerwenka; Ernst Kubista; Ambros V Huber Journal: Clin Exp Metastasis Date: 2006-07-07 Impact factor: 5.150
Authors: Charles T Miller; Justin R Moy; Lin Lin; Matthew Schipper; Daniel Normolle; Dean E Brenner; Mark D Iannettoni; Mark B Orringer; David G Beer Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Mahboubeh S Noori; Sarah J Bodle; Christian A Showalter; Evan S Streator; David S Drozek; Monica M Burdick; Douglas J Goetz Journal: Cell Mol Bioeng Date: 2020-01-21 Impact factor: 2.321
Authors: Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo Journal: Cell Mol Life Sci Date: 2022-02-03 Impact factor: 9.261
Authors: Daysha Ferrer-Torres; Derek J Nancarrow; Rork Kuick; Dafydd G Thomas; Ernest Nadal; Jules Lin; Andrew C Chang; Rishindra M Reddy; Mark B Orringer; Jeremy M G Taylor; Thomas D Wang; David G Beer Journal: Oncotarget Date: 2016-08-23
Authors: Gita A Pathak; Renato Polimanti; Talisa K Silzer; Frank R Wendt; Ranajit Chakraborty; Nicole R Phillips Journal: BMC Cancer Date: 2020-10-02 Impact factor: 4.430